UNSPSC 51162101: Isoniazid/pyrazinamide/rifampin

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AM500. This VA Drug Class (AM500) classifies this compound as belonging to the group ANTITUBERCULARS.

UNSPSC 51162101 Isoniazid/pyrazinamide/rifampin is a Commodity code with little recent relevant activity aligned to its nominal pharmaceutical scope. The recent state and local opportunities tagged to this code actually solicit naloxone and drug deactivation systems, on-site pharmacy services, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and OTC products — none of which are isoniazid/pyrazinamide/rifampin combinations. This mismatch suggests the code is either used inconsistently in state and local procurement systems or the opportunities were misclassified; in either case, the code shows minimal activity for the specific tuberculosis-treatment medication it nominally describes.

The issuing bodies across the misaligned opportunities span multiple jurisdiction types: a county government (Seminole County, Florida), a county health authority (Hall County, Georgia), a state health agency (Texas HHS Commission), and a multi-state cooperative purchasing alliance (MMCAP, administered by Minnesota). Geographic spread includes Florida, Georgia, Texas, Minnesota, and Oregon. Representative opportunities include Seminole County's IFB for naloxone and drug deactivation systems (response deadline Jul 26, 2023); Hall County's RFQ/P for on-site pharmacy services (response deadline Jun 4, 2026); Texas HHS's RFI on direct-to-manufacturer prescriptions (posted Apr 3, 2026); and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products (response deadline Mar 26, 2026). Without authentic recent opportunities for isoniazid/pyrazinamide/rifampin procurement, this code offers limited signal for business development targeting.